Resources VIDEOS 0:40 2.5 years of possibility 1:15 Embark Now to Gain More 3:49 Expert Prof Subodh Verma VDO 3-Take the Lead, Act 00:48 Are your T2D patients on the right DPP4i dose? 00:38 DPP4i - Proven efficacy with no dose reduction 00:27 DPP4i – What efficacy to expect? 00:54 Efficacy, Safety, Simplicity all in one DPP4i 01:22 JENTADUETO® dosing information 00:38 Renally impaired patients - Are they on the right dose? 00:21 Restricting TRAJENTA® to only renally impaired patients 02:22 Causes for stroke and its Diagnosis 02:10 How to recognize Stroke? 01:18 Treatment 03:15 Actilyse Dosing 03:20 High Residual CV Risk 02:44 Effect On Honeycombing Efficacy 03:17 Efficacy with Concomitant Emphysema 00:57 Expert Opinion 03:20 Mechanism of Action 05:58 Survival Analysis 09:33 Patients Subgroup Analysis 02:03 Why was the data of the INPULSIS® and TOMORROW trials pooled? 03:20 EMPA-REG OUTCOME Results - Video 03:20 Value Proposition 02:23 Are patients with type 2 diabetes at elevated CV risk? 02:23 Is Jardiance a medication for both endocrinologists and cardiologists? 01:52 Is the glucose-lowering effect of Jardiance a barrier to cardiologists prescribing it? 06:36 Do you use Empagliflozin for CV risk reduction in T2DM patients? 02:46 Should we move beyond glucose lowering as the main treatment goal? 01:42 What are your thoughts on the 35% relative risk reduction? 02:22 What are your views on the 38% relative risk reduction in CV death with Jardiance? 01:56 What does lowering the risk of CV death? - John Wilding 01:51 What does lowering the risk of CV death? - Lars Ryden 02:29 What were the key findings from EMPA-REG OUTCOME? Load more Clinical studies Carmelina Cardiovascular Results - No HHF Carmelina Cardiovascular Results Carmelina Kidney Results - Lower Risk Of Albuminurea Carmelina Kidney Results Safety Trajenta Simplicity of Dosing Trajenta Simplicity Trajenta Efficacy vs Trajenta Efficacy Regardless of Age Trajenta Efficacy With Same Dose In Severe Renal Impairment Trajenta Efficacy With Same Dose Regardless of Kidney Function Carmelina Study Design Carmelina Study Inclusion Criteria Carmelina Trial Overview Trajenta Efficacy up to 104 Weeks vs Glimepride Trajenta Efficacy Added To Metformin Trajenta Efficacy Regardless of BMI Trajenta Efficacy vs Pioglitazone Actilyse Dosing 2 Symptoms of Stroke Treatment of Stroke EMPA-REG OUTCOME Trial Results Adverse Event Management Efficacy Superiority Over SU Main Benefits Dosing EMPA-REG OUTCOME Study Design How does Nintedanib benefit patients in preserving lung function? How does dosing and administration of Nintedanib help compliance of IPF patients? Is honeycombing in an HRCT, the sole detector of IPF? Jardiance vs GLP-1 EMPEROR Reduced results EMPEROR Reduced Renal Outcome Jardiance Efficacy Jardiance Safety Jardiance Dosing Load more